Design Therapeutics, Inc. DSGN
10.65 USD -0.15 (-1.39%)
At closeNov 10, 2026, 4:01 PM EST
10.65 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
10.36 Day range 10.93
6.81 52-week range 17.25
- YTD
- +13.54%
- 1 year
- +43.34%
News
benzinga.com RBC Capital Maintains Outperform on Design Therapeutics, Lowers Price Target to $19 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and lowers the price target from $20 to $19.
benzinga.com Design Therapeutics Q3 EPS $(0.32) Beats $(0.35) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.35) by 8.57 percent. This is a 6.67 percent decrease over losses of…
globenewswire.com Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway…
seekingalpha.com Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. The company's 4-week phase 1/2 RESTORE-FA data showed strong…
benzinga.com Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26 Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
defenseworld.net Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat…
defenseworld.net Bank of New York Mellon Corp Purchases New Stake in Design Therapeutics, Inc. $DSGN Bank of New York Mellon Corp acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ: DSGN) in the undefined quarter, according to its most recent Form 13F filing with the Securities…
globenewswire.com Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
defenseworld.net BlackRock Inc. Takes Position in Design Therapeutics, Inc. $DSGN BlackRock Inc. acquired a new position in Design Therapeutics, Inc. (NASDAQ: DSGN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and…
benzinga.com Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after beating estimates, other stocks also drop in pre-market.
247wallst.com Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different…
benzinga.com Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of…
globenewswire.com Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending…- benzinga.com Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1 Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in…
globenewswire.com Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design…
seekingalpha.com Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA.…
globenewswire.com Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
benzinga.com TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
benzinga.com Design Therapeutics Stock Wobbles After Rare Genetic Disease Data Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
benzinga.com Design Therapeutics Stock Wobbles After Rare Genetic Disease Data Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.
benzinga.com Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech stocks drop. NAHB/Wells Fargo Housing Market Index up to 37.
benzinga.com Nasdaq Down 200 Points; Brady Earnings Top Views US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs,…
seekingalpha.com Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
benzinga.com Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability Score Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced positive biomarker and clinical data…
globenewswire.com Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing
globenewswire.com Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,…
benzinga.com Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares declined 0.8% to close at $95.43.
zacks.com Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.
benzinga.com Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21 Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $18 to $21.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
seekingalpha.com Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 6.45 percent increase over losses of…
globenewswire.com Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and…- benzinga.com Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15 Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.
- benzinga.com RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform and raises the price target from $13 to $14.
- benzinga.com Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.35) by 23.3 percent. This is a 12.5 percent decrease over losses of…
globenewswire.com Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
benzinga.com Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18 Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.- benzinga.com Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14 Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.
benzinga.com Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - benzinga.com RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13 RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perform to Outperform and raises the price target from $6 to $13.
- benzinga.com RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6 RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and raises the price target from $5 to $6.
benzinga.com Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. This is a 30.43 percent decrease over losses of…- benzinga.com Design Therapeutics Gets Clearance To Start Dosing DM1 Participants In Phase 1 Multiple-Ascending Dose Study Of DT-818 In Australia In H1 2026 Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress and updated milestones…
benzinga.com Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, signaling confidence in their potential for outsized returns.- benzinga.com Design Therapeutics Q2 EPS $(0.34) Misses $(0.33) Estimate Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 61.9 percent decrease over losses of…
- benzinga.com Design Therapeutics Submitted An Investigational New Drug Application For DT-216P2 With The FDA, The Company Received A Clinical Hold Notice On The IND Application From FDA Noting Nonclinical Deficiencies Further details will be provided in an official letter from FDA within 30 days and the company plans to address their questions, once received.IND Application Submitted to Expand RESTORE-FA Trial to…
- benzinga.com Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenous Infusion In Its RESTORE-FA Open-label Phase 1/2 Multiple-ascending Dose Trial Of Dt-216P2, Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Demonstrated Favorable Safety and Pharmacokinetics The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of IV and subcutaneous administration of DT-216P2 in patients with FA. DT-216P2…